# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Voltaire (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN002-SYN
- Date: 2026-04-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Honorine Delacroix-Mensah, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for primary care visit for three weeks of visible blood in the urine and difficult urination at 83. **S**

## Objective

Urine red cells: 75 /[HPF] (high); Urine white cells: 8 /[HPF] (high); IPSS: 22; Post-void residual (bladder scan): 460 mL (high); Hemoglobin: 11.6 g/dL (low); White blood cells: 7.8 10*3/uL; Platelets: 268 10*3/uL; Sodium: 138 mmol/L; Potassium: 5 mmol/L; Bicarbonate: 21 mmol/L (low); BUN: 34 mg/dL (high); Creatinine: 1.68 mg/dL (high); eGFR: 40 mL/min/1.73 m² (low); Glucose: 96 mg/dL; PSA: 6.4 ng/mL (high). All results are synthetic.

BP 138/72 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 96% on room air; weight 54.2 kg; BMI 18.8 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluation; Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheter; Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier); Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemas. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Stopped: Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter) **S**
- Started: Tamsulosin 0.4 mg oral capsule, one capsule at bedtime **S**
- Continued without change: Polyethylene glycol 3350, 17 g in a glass of water once daily **S**

## Plan

- Hematuria evaluation: urinalysis with microscopy, urine culture, urine cytology, blood count, kidney function, multiphasic CT urography with CT of the chest, and cystoscopy. Guideline: Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Urology consultation for gross hematuria with chronic retention: cystoscopy, resection if a tumor is found, the voiding trial, and the meaning of the PSA. Guideline: Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Retention: indwelling catheter now, tamsulosin at bedtime, catheter care teaching, then a trial without catheter with a bladder scan; IPSS and post-void residual at each visit. Guideline: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Medication review: stop the diphenhydramine sleep aid and the over-the-counter sodium phosphate enemas; keep polyethylene glycol; cut coffee to two cups a day, none after noon; sleep advice without sedatives. Guideline: American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018) **S**
- Shared decision on PSA testing: drawn before the catheter to interpret an enlarged, firm prostate, with the understanding that a raised value at 83 would lead to biopsy only if it would change treatment. Guideline: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Prostate Cancer: Screening (2018) **S**
